[Form 4] Immix Biopharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Immix Biopharma insider purchase: Gabriel Morris, reporting as a Director and CFO, purchased 2,600 shares of Immix Biopharma, Inc. (IMMX) on 09/16/2025 at a price of $1.97 per share. After the transaction he reports 290,659 shares directly beneficially owned and additional indirect holdings of 270,844 shares through Alwaysraise LLC and 24,141 shares through Alwaysraise Ventures/AVILP, with footnotes clarifying his managerial roles and disclaimer of beneficial ownership except for pecuniary interest. The Form 4 is signed by Gabriel Morris on 09/17/2025.

Insights

Financial Analyst

TL;DR: A routine insider purchase: CFO/Director bought 2,600 shares at $1.97, increasing direct holdings to 290,659 shares.

This transaction is a straightforward open-market purchase by a senior officer and director. The size of the purchase (2,600 shares) is small relative to the total reported holdings and does not by itself indicate a material change in ownership or corporate control. The filing clarifies indirect holdings through related entities with standard disclaimers of beneficial ownership except for pecuniary interest, which is customary for managing partners of investment vehicles.

Corporate Governance Expert

TL;DR: Governance disclosure appears complete: roles, relationships, and indirect holdings are disclosed with standard footnotes.

The Form 4 properly discloses both direct and indirect holdings and identifies the reporting person as CFO and Director. Footnotes explain the reporting person’s managerial relationships to Alwaysraise LLC and Alwaysraise Ventures and include disclaimers of beneficial ownership, which aligns with common governance practice for managers of investment entities. The signature and transaction date are present, meeting disclosure requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Morris Gabriel S

(Last) (First) (Middle)

C/O IMMIX BIOPHARMA, INC.

11400 WEST OLYMPIC BLVD., SUITE 200

(Street)

LOS ANGELES CA 90064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immix Biopharma, Inc. [ IMMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2025		P		2,600	A	$1.97	290,659	D
Common Stock								270,844	I	See footnote(1)
Common Stock								24,141	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise LLC ("Alwaysraise") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by Alwaysraise, except to the extent of his pecuniary interest therein.

2. Gabriel Morris is the Managing Partner of Alwaysraise Ventures I Investments, LLC ("Alwaysraise Ventures"), the general partner of Alwaysraise Ventures I, LP. ("AVILP") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by AVILP, except to the extent of his pecuniary interest therein.

	/s/ Gabriel Morris	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did IMMX reporting person Gabriel Morris do on 09/16/2025?

He purchased 2,600 shares of Immix Biopharma at $1.97 per share, reported on a Form 4 filed and signed 09/17/2025.

How many IMMX shares does Gabriel Morris report owning after the transaction?

He reports 290,659 shares directly and indirect holdings of 270,844 and 24,141 shares via related entities, per the Form 4.

What roles does the reporting person hold at IMMX?

The Form 4 identifies Gabriel Morris as a Director and as an Officer (CFO) of Immix Biopharma.

What do the footnotes on the Form 4 explain?

Footnotes state Mr. Morris is Managing Partner/Sole Member of Alwaysraise LLC and Managing Partner of Alwaysraise Ventures, with rights to vote and dispose of securities held by those entities and disclaimers of beneficial ownership except for pecuniary interest.

Is this Form 4 filing compliant with disclosure requirements?

Yes; the filing includes transaction date, type (purchase), number of shares, price, post-transaction holdings, relationship to issuer, explanatory footnotes, and a signature dated 09/17/2025.